SCHEMBL2144116

SCHEMBL2144116

COc1ccc(Br)nc1Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR4 O95977 1/20 0.43
NQO2 P16083 6/20 0.41
NQO1 P15559 1/20 0.37
KDM4E B2RXH2 3/20 0.36
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA7 P43166 2/20 0.36
CA9 Q16790 2/20 0.36
CA14 Q9ULX7 2/20 0.36
CA4 P22748 1/20 0.36
ALDH1A1 P00352 4/20 0.35
MAPT P10636 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ACHE P22303 1/20 0.34
IDO1 P14902 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29769759 1.00 S1PR4 (0.43) S1PR4NQO2NQO1KDM4ECA12
SCHEMBL20394372 0.84 POLB (0.41) S1PR4NQO2NQO1KDM4ECA12
SCHEMBL31414709 0.84 POLB (0.41) S1PR4NQO2NQO1KDM4ECA12
SCHEMBL14971502 0.84 NQO2 (0.40) NQO2NQO1KDM4ECA12CA1
SCHEMBL3792156 0.79 S1PR4 (0.47) S1PR4NQO2KDM4EALDH1A1MAPT
SCHEMBL4573187 0.79 KDM4E (0.50) NQO2NQO1KDM4ECA12CA1
SCHEMBL18611232 0.79 NQO2 (0.37) NQO2NQO1KDM4EALDH1A1MAPT
SCHEMBL16043514 0.77 S1PR4 (0.46) S1PR4NQO2NQO1KDM4EALDH1A1
SCHEMBL5455137 0.77 NQO2 (0.39) NQO2NQO1CA12CA1CA2
SCHEMBL3464576 0.77 NQO2 (0.43) NQO2NQO1KDM4ECA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3743068-B1 COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS EXELIXIS INC (US) 2026-04-29 EP disclosed
US-20260108535-A1 COMPOUNDS USEFUL TO TREAT PAIN AMNEAL PHARMACEUTICALS LLC (US) 2026-04-23 US disclosed
US-12527808-B2 Compounds useful to treat pain AMNEAL PHARMACEUTICALS LLC (US) 2026-01-20 US disclosed
US-12195475-B2 Compounds for the treatment of kinase-dependent disorders EXELIXIS, INC. (US) 2025-01-14 US disclosed
CN-111936487-B Compounds for the treatment of kinase dependent disorders 埃克塞里艾克西斯公司 2024-07-09 CN disclosed
US-20240150371-A1 Compounds for the Treatment of Kinase-Dependent Disorders EXELIXIS, INC. 2024-05-09 US disclosed
US-20230374024-A1 Compounds for the Treatment of Kinase-Dependent Disorders EXELIXIS, INC. 2023-11-23 US disclosed
US-20230374024-A1 Compounds for the Treatment of Kinase-Dependent Disorders EXELIXIS, INC. 2023-11-23 US disclosed
US-11708367-B2 Compounds for the treatment of kinase-dependent disorders EXELIXIS, INC. (US) 2023-07-25 US disclosed
US-11708367-B2 Compounds for the treatment of kinase-dependent disorders EXELIXIS, INC. (US) 2023-07-25 US disclosed
EP-2344494-A1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS Signal Pharmaceuticals, LLC (US) 2011-07-20 EP disclosed
US-20100278833-A1 THIOPHENE-IMIDAZOPYRIDINES 4SC AG (DE) 2010-11-04 US disclosed
US-20100093698-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2010-04-15 US disclosed
WO-2010027500-A1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2010-03-11 WO disclosed
EP-2017277-A1 Thiophene-imidazopyridines 4SC AG (DE) 2009-01-21 EP disclosed
WO-2009003911-A1 THIOPHENE-IMIDAZOPYRIDINES 4SC AG (DE) 2009-01-08 WO disclosed
CN-101103017-A Novel aminopyridine derivatives having Aurora-A selective inhibitory action BANYU PHARMA CO LTD (JP) 2008-01-09 CN disclosed
EP-0949248-B1 6-(NONSUBSTITUTED OR SUBSTITUTED) PHENOXYPICOLINIC ACIDS, PROCESS OF PREPARING THE SAME, AND AGRICULTURAL/HORTICULTURAL GERMICIDES CONTAINING THE SAME KUREHA CHEMICAL IND CO LTD (JP) 2003-10-08 EP disclosed
US-6200933-B1 LOW TOXICITY TO HUMANS AND CATTLE KUREHA KAGAKU KABUSHIKI KAISHA (JP) 2001-03-13 US disclosed
EP-0949248-A1 6-(NONSUBSTITUTED OR SUBSTITUTED) PHENOXYPICOLINIC ACIDS, PROCESS OF PREPARING THE SAME, AND AGRICULTURAL/HORTICULTURAL GERMICIDES CONTAINING THE SAME KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1999-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12527808-B2 Compounds useful to treat pain BDKRB2, TRPV1, BDKRB1 S1PR4 1147/4885NQO2 2755/4885NQO1 1525/4885
US-11708367-B2 Compounds for the treatment of kinase-dependent disorders ERBB2, ERBB3, MAP3K6 S1PR4 3716/4885NQO2 3516/4885NQO1 1303/4885
US-20260108535-A1 COMPOUNDS USEFUL TO TREAT PAIN BDKRB2, BDKRB1, AVPR1B S1PR4 684/4885NQO2 3668/4885NQO1 2302/4885
US-20230374024-A1 Compounds for the Treatment of Kinase-Dependent Disorders ERBB2, ERBB3, MAP3K6 S1PR4 3716/4885NQO2 3516/4885NQO1 1303/4885
US-20100278833-A1 THIOPHENE-IMIDAZOPYRIDINES PIKFYVE, PIP4K2B, PIP5K1B S1PR4 3037/4885NQO2 2336/4885NQO1 4132/4885
US-20240150371-A1 Compounds for the Treatment of Kinase-Dependent Disorders ERBB2, MAP3K6, PRKCH S1PR4 3881/4885NQO2 3491/4885NQO1 1348/4885
US-12195475-B2 Compounds for the treatment of kinase-dependent disorders ERBB2, ERBB3, MAP3K6 S1PR4 3716/4885NQO2 3516/4885NQO1 1303/4885
US-20100093698-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH MAP3K2, MAP3K1, MAP3K3 S1PR4 2721/4885NQO2 1006/4885NQO1 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.